Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes

[1]  R. Ferrari,et al.  Uric acid and coronary artery disease: An elusive link deserving further attention. , 2016, International journal of cardiology.

[2]  M. Goicoechea,et al.  Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  N. Rashid,et al.  Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in an Integrated Healthcare System , 2015, The Journal of Rheumatology.

[4]  F. D. de Abajo,et al.  Allopurinol use and risk of non-fatal acute myocardial infarction , 2015, Heart.

[5]  N. Limdi,et al.  Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation , 2015, Circulation. Cardiovascular quality and outcomes.

[6]  Francisco Javier Bonilla-Escobar,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) in the International Journal of Medical Students , 2014 .

[7]  M. Kanbay,et al.  Effects of Allopurinol on Endothelial Dysfunction: A Meta-Analysis , 2014, American Journal of Nephrology.

[8]  Swu-Jane Lin,et al.  Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat , 2014, Postgraduate medicine.

[9]  L. Abenhaim,et al.  Impact of allopurinol on risk of myocardial infarction , 2014, Annals of the rheumatic diseases.

[10]  M. Goldacre,et al.  Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. , 2013, Rheumatology.

[11]  S. Ito,et al.  Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study , 2013, Clinical and Experimental Nephrology.

[12]  Brian Sauer,et al.  The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.

[13]  A. Struthers,et al.  Allopurinol: novel indications in cardiovascular disease , 2012, Heart.

[14]  Hyon K. Choi,et al.  Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. , 2012, The American journal of medicine.

[15]  J. Greenberg,et al.  Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout , 2012, The Journal of Rheumatology.

[16]  N. Espinola-Zavaleta,et al.  Effect of the Treatment with Allopurinol on the Endothelial Function in Patients with Hyperuricemia , 2012, Endocrine research.

[17]  W. Frishman,et al.  Allopurinol as a Cardiovascular Drug , 2011, Cardiology in review.

[18]  Y. Solak,et al.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[19]  C. Lang,et al.  Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[20]  S. Schneeweiss,et al.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.

[21]  A. Dogan,et al.  Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients , 2011, Blood pressure.

[22]  Y. Chen,et al.  Impact of allopurinol use on urate concentration and cardiovascular outcome , 2011, British journal of clinical pharmacology.

[23]  Sebastian Schneeweiss,et al.  A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.

[24]  J. Kopec,et al.  Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study , 2010, Annals of the rheumatic diseases.

[25]  Hyon K. Choi,et al.  Hyperuricemia and coronary heart disease: A systematic review and meta‐analysis , 2010, Arthritis care & research.

[26]  J. Singh.  Accuracy of Veterans Affairs Databases for Diagnoses of Chronic Diseases , 2009, Preventing chronic disease.

[27]  C. Stefanadis,et al.  The role of oxidative stress in atherosclerosis. , 2009, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[28]  Hyon K. Choi,et al.  Hyperuricemia and risk of stroke: a systematic review and meta-analysis. , 2009, Arthritis and rheumatism.

[29]  B. Rovin,et al.  Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.

[30]  M. Walters,et al.  Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Stroke.

[31]  G. Şener,et al.  Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome , 2008, Clinical Research in Cardiology.

[32]  J. Hodges,et al.  Quality of care for gout in the US needs improvement. , 2007, Arthritis and rheumatism.

[33]  D. Furst,et al.  Gout and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[34]  P. O’Connor,et al.  Are Claims Data Accurate Enough to Identify Patients for Performance Measures or Quality Improvement? The Case of Diabetes, Heart Disease, and Depression , 2006, American journal of medical quality : the official journal of the American College of Medical Quality.

[35]  C. Szabó,et al.  Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol , 2006, Pharmacological Reviews.

[36]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[37]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[38]  Donald R. Miller,et al.  Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. , 2004, Diabetes care.

[39]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[40]  K. Tuttle,et al.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? , 2003, Hypertension.

[41]  S. Gabriel,et al.  The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.